Skip to main content

Table 1 Population-based and clinical samples

From: Shared genetic influences between dimensional ASD and ADHD symptoms during child and adolescent development

Sample

Source

Ethnicity

Number

Phenotype/diagnosis

ALSPACa,b

General population

White European

5612 (7 y): age(SE) = 6.79(0.11)

ADHD symptoms (mother-report) as assessed with SDQ ADHD scores

5678 (10 y): age(SE) = 9.65(0.12)

5259 (12 y): age(SE) = 11.72(0.13)

5072 (13 y): age(SE) = 13.16(0.18)

4164 (17 y): age(SE) = 16.84(0.18)

ALSPACa,b

General population

White European

5551 (8 y): age(SE) = 7.65(0.14)

Social-communication difficulties (mother-report) as assessed with SCDC scores

5460 (11 y): age(SE) = 10.72(0.13)

5060 (14 y): age(SE) = 13.90(0.15)

4174 (17 y): age (SE) = 16.84(0.36)

PGC-ADHDc

Clinical ADHD sample

White European

4163 cases and 12,040 controls/pseudo-controls

ADHD or hyperkinetic disorder

PGC-ASDa

Clinical ASD sample

White European

5305 cases; 5305 pseudo-controls

ASD

  1. ADHD attention deficit hyperactivity disorder, ALSPAC Avon Longitudinal study of Parents and Children, ASD autism spectrum disorder, PGC-ADHD ADHD collection of the Psychiatric Genomics Consortium (PGC), PGC-ASD ASD collection of the PGC, SCDC Social and Communication Disorders Checklist, SDQ-ADHD ADHD subscale of the Strength and Difficulties Questionnaire, y age in years
  2. aSamples were imputed to a 1000 genomes reference (Phase1_v3)
  3. bALSPAC individuals who were related to participants of the PGC-ADHD sample were excluded
  4. cSamples were imputed to HapMap3 CEU and TSI